Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

An Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality Disorder

To see complete record on, please visit this link

Id: NCT05399498

Organisation Name: University of Chicago

Overal Status: Not yet recruiting

Start Date: December 2022

Last Update: August 5, 2022

Lead Sponsor: University of Chicago

Brief Summary: The primary objective of the study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD).

  • Borderline Personality Disorder
  • Major Depressive Disorder

Total execution time in seconds: 0.21039295196533